TherimuneX Pharmaceuticals is a drug discovery and development company located at the Pennsylvania Biotechnology Center in Doylestown, PA. The Company’s drug development platform relates to our discovery of a new family of endogenous lipopeptides and their immune regulating properties. Induced in response to cell injury, these peptides activate the innate arm of the immune response. This discovery has enabled us to directly relate cell injury to the pro-inflammatory immune cascade and formulate a model for the immunopathology underlying many human diseases.